Moderna, Inc. — Director's Dealing 2023

Feb 24, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2023-02-22

Reporting Person: Bancel Stephane (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-02-22	Common Stock	M	40000	$.99	Acquired	5451946	Direct
2023-02-22	Common Stock	S	10472	$157.87	Disposed	5441474	Direct
2023-02-22	Common Stock	S	20303	$158.53	Disposed	5421171	Direct
2023-02-22	Common Stock	S	8725	$159.59	Disposed	5412446	Direct
2023-02-22	Common Stock	S	500	$160.28	Disposed	5411946	Direct
2023-02-23	Common Stock	M	40000	$.99	Acquired	5451946	Direct
2023-02-23	Common Stock	S	7314	$144.45	Disposed	5444632	Direct
2023-02-23	Common Stock	S	7486	$145.25	Disposed	5437146	Direct
2023-02-23	Common Stock	S	12890	$146.75	Disposed	5424256	Direct
2023-02-23	Common Stock	S	8256	$147.43	Disposed	5416000	Direct
2023-02-23	Common Stock	S	3754	$148.27	Disposed	5412246	Direct
2023-02-23	Common Stock	S	300	$149.86	Disposed	5411946	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-02-22	Stock Option (Right to Buy)	$.99	M	40000	Disposed	2023-08-19	Common Stock (40000)	Direct
2023-02-23	Stock Option (Right to Buy)	$.99	M	40000	Disposed	2023-08-19	Common Stock (40000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	9050372	Indirect
Common Stock	6564880	Indirect

Footnotes

F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018, as last amended on March 15, 2022, and as further described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on May 24, 2022.

F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $157.13 to $158.13. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $158.14 to $159.14. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $159.15 to $160.11. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F5: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $160.19 to $160.42. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F6: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $143.81 to $144.80. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F7: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $144.84 to $145.79. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F8: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $146.03 to $147.03. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F9: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $147.04 to $148.03. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F10: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $148.05 to $148.76. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F11: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $149.42 to $150.21. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F12: These shares are owned directly by Boston Biotech Ventures, LLC ("Boston Biotech"). The reporting person is the majority equity unit holder and the sole managing member of Boston Biotech. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

F13: These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

F14: This option is fully vested and exercisable.